OPKO In Good Health, TNXP Gets Uplisted, SGYP On Track, Watch Out For VICL

(RTTNews) - Vical Inc. (VICL) will be reporting top-line results from a phase III trial of its lead compound Allovectin-7 before the opening of trading on Monday, August 12, and conduct a conference call and webcast to discuss the results at 8:00 a.m. Eastern Time today.

Allovectin-7 is being evaluated to prove its superiority over the current first-line chemotherapies like Dacarbazine or Temozolomide in patients with metastatic melanoma.

VICL closed Friday's trading at $3.58, down 3.76%.

OPKO Health Inc. (OPK) on Friday said that its second quarter net loss improved as revenue more than doubled compared to the year-ago quarter.

Top-line results from a phase III trial of Rolapitant, which OPKO out-licensed to biopharmaceutical company TESARO Inc., are anticipated in the second half of 2013. Rolapitant is under phase III testing for the treatment of chemotherapy-induced nausea and vomiting.

OPK closed Friday's trading at $7.49. In after-hours, the stock was up 0.53% to $7.53.

Neuralstem Inc. (CUR) expects to begin a phase II trial of its investigational drug, NSI-566, in patients with amyotrophic lateral sclerosis in August or September of this year. The company also anticipates data from a phase Ib trial of NSI-189 for major depressive disorder to be available in the second half of the year.

CUR shed 0.64% in Tuesday's trading to close at $1.56.

Tonix Pharmaceuticals Holding Corp. (TNXP) ceased trading on the OTC QB and got uplisted to the NASDAQ Capital Market on August 9, 2013. The company also announced the pricing of an offering of 2.68 million units at $4.25 per unit, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock.

The company expects to get gross proceeds of $11.4 million from the offering, which is scheduled to close on August 14, 2013. A phase 2b/3 clinical trial of TNX-102 SL for the treatment of fibromyalgia is in process to begin in the third quarter of 2013.

TNXP plunged more than 30% in Friday's trading to close at $3.84.

Synergy Pharmaceuticals Inc. (SGYP) expects reporting top line data from a phase 2b clinical trial of its investigational drug Plecanatide in patients with IBS-C (irritable bowel syndrome with constipation) in the first quarter of 2014. A pivotal phase III program evaluating the safety and efficacy of Plecanatide in chronic idiopathic constipation patients is expected to be initiated in the fourth quarter of 2013.

SGYP closed Friday's trading 0.67% higher at $4.50.